Human Genome Sciences Inc, which has rejected a hostile $13-per-share offer from GlaxoSmithKline, has adopted a short-term stockholder rights plan to fend off such unwanted attention.
Rockville-based Human Genome (NASDAQ: HGSI) said in a statement announcing the plan that it had declared a dividend of one share purchase right for each share of the company's common stock held of record at the close of business on May 29.
To read the full, original article click on this link: Human Genome Sciences adopts stockholder rights plan - Baltimore Business Journal
